---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-024112"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:54:14.403300+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ArriVent reports FY2025 net loss of $166.3M; cash of $312.8M funds into 3Q 2027

## Summary
- Cash and investments of $312.8M as of Dec 31, 2025; expected to fund operations into 3Q 2027.
- Net loss $166.3M in FY2025 vs $80.5M in FY2024; R&D expenses $153.4M (incl. one-time payment to Lepu).
- Topline pivotal Phase 3 data for firmonertinib in first-line EGFR exon20ins NSCLC expected mid-2026.
- Phase 3 ALPACCA study for firmonertinib in EGFR PACC mutant NSCLC dosed first patient in Dec 2025.
- ADC lead ARR-217 in Phase 1 dose escalation; IND clearance received; first patient dosed March 2026.

## SEC filing metadata
- accession: 0001104659-26-024112
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465926024112/0001104659-26-024112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465926024112/avbp-20260305x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-024112
- JSON: https://secwatch.observer/filing/0001104659-26-024112.json
- Plain text: https://secwatch.observer/filing/0001104659-26-024112.txt

## Key facts
- Earnings Releases
  ArriVent BioPharma, Inc. reported the year ended December 31, 2025 results: net income Net loss was $166.3 million.
  - Period: the year ended December 31, 2025
  - Net income: Net loss was $166.3 million
  - Result: reported results
  source text: ArriVent BioPharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1868279/000110465926024112/0001104659-26-024112-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.